论文部分内容阅读
目的:观察莫西沙星联合抗痨药物化疗方案治疗耐多药肺结核(MDR-TB)的临床疗效和安全性。方法:84例MDR-TB患者随机分为两组:治疗组(n=42)采用莫西沙星(M)联合对氨基水杨酸异烟肼片(D)、利福喷丁(L)、吡嗪酰胺(Z)、乙胺丁醇(E);对照组(n=42)采用左氧氟沙星(V)联合D、L、Z、E;疗程均为18个月。观察和比较两组不同时期痰菌阴转率、临床疗效及不良反应发生率。结果:疗程结束时,治疗组痰菌阴转率为90.5%、空洞闭合率为58.6%,临床总有效率为83.3%,均显著高于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论:莫西沙星联合抗痨药物化疗方案治疗MDR-IB能加速痰菌阴转、加快空洞闭合,临床疗效显著。
Objective: To observe the clinical efficacy and safety of moxifloxacin and anti-tuberculosis chemotherapy in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB). Methods: Eighty-four patients with MDR-TB were randomly divided into two groups. The treatment group (n = 42) was treated with moxifloxacin (M) in combination with isoniazid tablets (D), rifapentine (L) (Z) and ethambutol (E). The control group (n = 42) received levofloxacin (V) combined with D, L, Z and E for 18 months. The sputum negative conversion rate, clinical efficacy and incidence of adverse reactions in two groups were observed and compared. Results: At the end of treatment, the sputum negative conversion rate was 90.5%, the void closure rate was 58.6% and the total clinical effective rate was 83.3% in the treatment group, which were significantly higher than those in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Moxifloxacin combined with anti-tuberculosis chemotherapy regimen in the treatment of MDR-IB can speed up the sputum negative conversion, speed up the cavity closure, the clinical effect was significant.